Literature DB >> 28368925

A Novel Numerical Scoring System for Melanoma Tumor-infiltrating Lymphocytes Has Better Prognostic Value Than Standard Scoring.

Gerald Saldanha1, Katarina Flatman, Kah Wee Teo, Mark Bamford.   

Abstract

The purpose of this study was to evaluate the prognostic value of tumor-infiltrating lymphocytes (TILs) in melanoma and to determine whether a simpler numerical scoring system would be more effective. In total, 655 patients presenting to a UK teaching hospital with primary invasive melanoma were analyzed. TILs were rescored using the standard Clark's method and univariable and multivariable analyses of the effect of TILs on overall survival (OS), disease-specific survival (DSS), and metastasis-free survival (MFS) was assessed using Cox regression. In total, 30 (5%) melanomas showed absent, 464 (71%) nonbrisk, and 161 (24%) brisk TILs. There was a statistically significant relationship between TILs and Breslow thickness, age, melanoma type, mitotic rate, and histologic regression. TIL grade was a significant predictor of MFS in multivariable analysis (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.25-0.77) but was not significant for OS or DSS. By contrast, when a simple numerical TIL percentage score was used this was a strong predictor of OS (HR, 0.55; 95% CI, 0.38-0.78), DSS (HR, 0.25; 95% CI, 0.14-0.44), and MFS (HR, 0.32; 95% CI, 0.21-0.51) in multivariable analysis. The percentage TIL score was also significant when adjusted for the prognostic gold standard, American Joint Committee on Cancer stage: OS (HR, 0.66; 95% CI, 0.46-0.95), DSS (HR, 0.33; 95% CI, 0.19-0.60), and MFS (HR, 0.41; 95% CI, 0.26-0.65). The TIL percentage score was subsequently validated in new cases. In summary, this study strongly confirms that higher amounts of TILs are associated with better prognosis and in addition demonstrates the value of a simplified numerical TIL scoring system.

Entities:  

Mesh:

Year:  2017        PMID: 28368925      PMCID: PMC6171741          DOI: 10.1097/PAS.0000000000000848

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  16 in total

1.  Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.

Authors:  John F Thompson; Seng-Jaw Soong; Charles M Balch; Jeffrey E Gershenwald; Shouluan Ding; Daniel G Coit; Keith T Flaherty; Phyllis A Gimotty; Timothy Johnson; Marcella M Johnson; Stanley P Leong; Merrick I Ross; David R Byrd; Natale Cascinelli; Alistair J Cochran; Alexander M Eggermont; Kelly M McMasters; Martin C Mihm; Donald L Morton; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.

Authors:  Manuela F Azzola; Helen M Shaw; John F Thompson; Seng-Jaw Soong; Richard A Scolyer; Geoffrey F Watson; Marjorie H Colman; Yuting Zhang
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

3.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Authors:  W H Clark; L From; E A Bernardino; M C Mihm
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

4.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.

Authors:  Farhad Azimi; Richard A Scolyer; Pavlina Rumcheva; Marc Moncrieff; Rajmohan Murali; Stanley W McCarthy; Robyn P Saw; John F Thompson
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

5.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

6.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

7.  The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.

Authors:  Anne Brecht Francken; Helen M Shaw; John F Thompson; Seng-jaw Soong; Neil A Accortt; Manuela F Azzola; Richard A Scolyer; Gerald W Milton; William H McCarthy; Marjorie H Colman; Vincent J McGovern
Journal:  Ann Surg Oncol       Date:  2004-03-15       Impact factor: 5.344

Review 8.  Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.

Authors:  Nayoung Lee; Labib R Zakka; Martin C Mihm; Tobias Schatton
Journal:  Pathology       Date:  2016-01-16       Impact factor: 5.306

9.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.

Authors:  C G Clemente; M C Mihm; R Bufalino; S Zurrida; P Collini; N Cascinelli
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

10.  REporting recommendations for tumour MARKer prognostic studies (REMARK).

Authors:  L M McShane; D G Altman; W Sauerbrei; S E Taube; M Gion; G M Clark
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

View more
  17 in total

1.  A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis.

Authors:  Yanding Zhao; Evelien Schaafsma; Ivan P Gorlov; Eva Hernando; Nancy E Thomas; Ronglai Shen; Mary Jo Turk; Marianne Berwick; Christopher I Amos; Chao Cheng
Journal:  Mol Cancer Res       Date:  2018-08-31       Impact factor: 5.852

2.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

3.  Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.

Authors:  Richard K Yang; Igor B Kuznetsov; Javed Khan; Paul M Sondel; Erik A Ranheim; Jun S Wei; Sivasish Sindiri; Berkley E Gryder; Vineela Gangalapudi; Young K Song; Viharkumar Patel; Jacquelyn A Hank; Cindy Zuleger; Amy K Erbe; Zachary S Morris; Renae Quale; KyungMann Kim; Mark R Albertini
Journal:  Clin Cancer Res       Date:  2020-03-09       Impact factor: 12.531

4.  Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.

Authors:  Aayoung Hong; Marco Piva; Sixue Liu; Gatien Moriceau; Roger S Lo; Willy Hugo; Shirley H Lomeli; Vincent Zoete; Christopher E Randolph; Zhentao Yang; Yan Wang; Jordan J Lee; Skylar J Lo; Lu Sun; Agustin Vega-Crespo; Alejandro J Garcia; David B Shackelford; Steven M Dubinett; Philip O Scumpia; Stephanie D Byrum; Alan J Tackett; Timothy R Donahue; Olivier Michielin; Sheri L Holmen; Antoni Ribas
Journal:  Cancer Discov       Date:  2020-12-14       Impact factor: 39.397

5.  Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.

Authors:  Wiebke Pruessmann; Julie Rytlewski; James Wilmott; Richard A Scolyer; Thomas S Kupper; Martin C Mihm; Grace H Attrill; Beatrice Dyring-Andersen; Paul Fields; Qian Zhan; Andrew J Colebatch; Peter M Ferguson; John F Thompson; Klaus Kallenbach; Erik Yusko; Rachael A Clark; Harlan Robins
Journal:  Nat Cancer       Date:  2020-01-20

6.  Is There a Relationship Between TILs and Regression in Melanoma?

Authors:  Steven Morrison; Gang Han; Faith Elenwa; John T Vetto; Graham Fowler; Stanley P Leong; Mohammed Kashani-Sabet; Barbara Pockaj; Heidi E Kosiorek; Jonathan S Zager; Jane L Messina; Nicola Mozzillo; Schlomo Schneebaum; Dale Han
Journal:  Ann Surg Oncol       Date:  2022-01-21       Impact factor: 5.344

Review 7.  HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer.

Authors:  Tristan A Barnes; Eitan Amir
Journal:  Br J Cancer       Date:  2017-07-13       Impact factor: 7.640

Review 8.  The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.

Authors:  Caroline S Jansen; Nataliya Prokhnevska; Haydn T Kissick
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 2.954

9.  The High Level of Tertiary Lymphoid Structure Is Correlated With Superior Survival in Patients With Advanced Gastric Cancer.

Authors:  Wenting He; Dachuan Zhang; Hong Liu; Tongbing Chen; Jun Xie; Lei Peng; Xiao Zheng; Bin Xu; Qing Li; Jingting Jiang
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244

10.  Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma.

Authors:  John A Barrett; Hongliang Cai; John Miao; Pranay D Khare; Paul Gonzalez; Jessica Dalsing-Hernandez; Geeta Sharma; Tim Chan; Laurence J N Cooper; Francois Lebel
Journal:  Cancer Gene Ther       Date:  2018-05-14       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.